<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565094</url>
  </required_header>
  <id_info>
    <org_study_id>17695A</org_study_id>
    <nct_id>NCT03565094</nct_id>
  </id_info>
  <brief_title>Single Dose of Lu AF28996 to Healthy Young Men</brief_title>
  <official_title>Interventional, Open-label, Single- and Sequential-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic Profile of Lu AF28996 in Healthy Young Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates how increasing doses of Lu AF28996 enters, moves through and exits the
      body when given by mouth to healthy young men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A of the study consists of 6 groups (Cohorts 1 to 6) with 3 subjects in each, with the
      possibility of 4 additional cohorts. In cohort 1, the subjects will receive a single dose of
      Lu AF28996 by mouth. Following evaluation of data from the first dose, the subjects in the
      following cohorts are planned to receive two single increasing doses by mouth of Lu AF28996
      on 2 separate days with a wash out (day or days without dosing) in between.

      Part B is an open-label three-period crossover study in healthy young men to compare the PK
      of an oral capsule formulation with that of an oral solution formulation and to evaluate food
      effect following oral capsule administration of Lu AF28996.The subjects will be randomised to
      one of the four treatment sequences
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Actual">August 21, 2019</completion_date>
  <primary_completion_date type="Actual">August 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC 0-inf</measure>
    <time_frame>From dosing to day 12 postdose</time_frame>
    <description>area under the plasma concentration-time curve of Lu AF28996</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>From dosing to day 12 postdose</time_frame>
    <description>maximum observed plasma concentration of Lu AF28996</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>From dosing to day 12 postdose</time_frame>
    <description>Oral clearance of Lu AF28996</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Treatment-Emergent Adverse Events</measure>
    <time_frame>From dosing to day 12 postdose</time_frame>
    <description>Safety and Tolerability based on the safety assessments (clinical safety laboratory tests, vital signs, weight and ECG parameters)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AF28996</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AF28996 solution, cohort depending dose
Part A:
Cohort 1: single oral dose of Lu AF28996
Cohorts 2-6: two single ascending oral doses of Lu AF28996 with a washout in between
Possibility of 4 additional cohorts (Cohorts 7 to 10), allowing for the investigation of a potential 13 additional subjects
Part B: 8 subjects (randomised to one of four treatment sequences)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF28996 solution</intervention_name>
    <description>Oral solution (0.1-0.2 mg/mL)
Following each cohort, a dosing conference will be held where tolerability, safety and preliminary PK results from the previous cohorts will be reviewed before deciding on the next doses</description>
    <arm_group_label>Lu AF28996</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF28996 capsule</intervention_name>
    <description>hard capsule orally QD: one dose lower than the highest dose level in part A</description>
    <arm_group_label>Lu AF28996</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterium:

        Healthy, young, non-smoking men aged ≥18 and ≤45 years and with a body mass index (BMI)
        ≥18.5kg/m2 and ≤30kg/m2 at the Screening Visit

        Other in- and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QPS Netherlands BV</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

